Conversely, there was a negative correlation between the expression of SETD4 and immune‐related pathways [such as TNFA signaling via NFKB, KRAS signaling upregulated, and Interferon Gamma (IFN‐γ) response] in BLCA, CHOL, and glioblastoma multiform (GBM) (Figure 4A). The gene discussed is KRAS; the disease is bladder transitional cell carcinoma.